Paul Grant1, Lorraine Lougee, Matthew Hirschtritt, Susan E Swedo. 1. Pediatrics and Developmental Neuropsychiatry Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA. paul.grant@nih.gov
Abstract
BACKGROUND:Obsessive-compulsive disorder (OCD) in childhood is often refractory to treatment. Riluzole, a glutamate antagonist, has theoretical support as an alternative pharmacological treatment and has demonstrated possible benefit in some open-label trials in adults with OCD. METHODS:Six subjects, ages 8-16 years, were enrolled in a 12-week open-label trial of riluzolefor OCD symptoms that had resisted prior treatments. OCD symptoms and adverse effects of drug were monitored. RESULTS: Four of 6 subjects had clear benefit, with reduction of more than 46% (39% overall) on Children's Yale-Brown Obsessive-Compulsive Scale, and "Much Improved" or "Very Much Improved" on the Clinical Global Impressions-Improvement scale. Two subjects had no clinically meaningful change in symptom severity by 12 weeks, but 1 subject improved thereafter. There were no adverse effects of drug sufficient to cause discontinuation or reduction of dose. All subjects elected to continue riluzole after the 12-week trial. CONCLUSIONS:Riluzole may be beneficial for treatment-resistant OCD in young subjects and seems well tolerated. A placebo-controlled trial of the drug is planned.
RCT Entities:
BACKGROUND:Obsessive-compulsive disorder (OCD) in childhood is often refractory to treatment. Riluzole, a glutamate antagonist, has theoretical support as an alternative pharmacological treatment and has demonstrated possible benefit in some open-label trials in adults with OCD. METHODS: Six subjects, ages 8-16 years, were enrolled in a 12-week open-label trial of riluzole for OCD symptoms that had resisted prior treatments. OCD symptoms and adverse effects of drug were monitored. RESULTS: Four of 6 subjects had clear benefit, with reduction of more than 46% (39% overall) on Children's Yale-Brown Obsessive-Compulsive Scale, and "Much Improved" or "Very Much Improved" on the Clinical Global Impressions-Improvement scale. Two subjects had no clinically meaningful change in symptom severity by 12 weeks, but 1 subject improved thereafter. There were no adverse effects of drug sufficient to cause discontinuation or reduction of dose. All subjects elected to continue riluzole after the 12-week trial. CONCLUSIONS:Riluzole may be beneficial for treatment-resistant OCD in young subjects and seems well tolerated. A placebo-controlled trial of the drug is planned.
Authors: Paul Daniel Arnold; Frank P Macmaster; Gregory L Hanna; Margaret A Richter; Tricia Sicard; Eliza Burroughs; Yousha Mirza; Phillip C Easter; Michelle Rose; James L Kennedy; David R Rosenberg Journal: Brain Imaging Behav Date: 2009-03-01 Impact factor: 3.978
Authors: Claudia Delgado-Acevedo; Sebastián F Estay; Anna K Radke; Ayesha Sengupta; Angélica P Escobar; Francisca Henríquez-Belmar; Cristopher A Reyes; Valentina Haro-Acuña; Elías Utreras; Ramón Sotomayor-Zárate; Andrew Cho; Jens R Wendland; Ashok B Kulkarni; Andrew Holmes; Dennis L Murphy; Andrés E Chávez; Pablo R Moya Journal: Neuropsychopharmacology Date: 2018-12-26 Impact factor: 7.853
Authors: Logan K Wink; Martin H Plawecki; Craig A Erickson; Kimberly A Stigler; Christopher J McDougle Journal: Expert Opin Emerg Drugs Date: 2010-09 Impact factor: 4.191
Authors: Dennis L Murphy; Pablo R Moya; Meredith A Fox; Liza M Rubenstein; Jens R Wendland; Kiara R Timpano Journal: Philos Trans R Soc Lond B Biol Sci Date: 2013-02-25 Impact factor: 6.237